Drug Trial Radar · NCT02411695
Study to Assess the Safety, Tolerability and Pharmacokinetics of Oral Brexpiprazole (OPC- 34712) in Adolescents With Schizophrenia
Last checked: Nov 20, 2026Latest source record: Apr 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
43
Actual
Start
Mar 2015
Primary completion
Jan 1, 2017
Study completion Jan 1, 2017
Sponsor
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
- Sponsor type
- Industry
- Collaborators
- H. Lundbeck A/S
- First posted
- Apr 8, 2015
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 13 years, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the safety, tolerability and pharmacokinetics (PK) of oral brexpipirazole in adolescent subjects with schizophrenia or Other Related Psychiatric Disorders.
Conditions
- Schizophrenia
Interventions
Brexpiprazole (OPC-34712)Drug
Subjects who are deemed eligible for the trial will be assigned to a dosing cohort and will enter a Dose Titration Phase during which they will receive a starting dose of brexpiprazole for 2 to 10 days based on their assigned titration schedule. The Dose Titration Phase may be extended up to a maximum of 14 days, based on the observed safety and tolerability profile of the previous cohort's Dose Titration Phase. Following the Dose Titration Phase, subjects will enter the Fixed Dose Phase and will be administered the assigned dose for that cohort for 14 days.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Reported Adverse Events (AEs) at 30 day Follow-UpTime frame: 30 day Follow-Up
- Change from Baseline to Day 17 in Vital SignsTime frame: Baseline to Day 17
- Change from Baseline to Day 17 ECGsTime frame: Baseline to Day 17
- Change from Baseline to Day 17 HematologyTime frame: Baseline to Day 17
- Change from Baseline to Day 14 Physical examinationTime frame: Baseline to Day 14
- Change from Baseline to Day 17 Body weightTime frame: Baseline to Day 17
- Change from Baseline to Day 17 Serum chemistryTime frame: Baseline to Day 17
- Change from Baseline to Day 17 UrinalysisTime frame: Baseline to Day 17
- Maximal peak steady-state plasma concentrationTime frame: At Day 14
- Minimum trough steady-state plasma concentrationTime frame: At Day 14
- Time to maximum peak steady-state plasma concentrationTime frame: At Day 14
- Area under the concentration-time curve during the dosing interval at steady-stateTime frame: At Day 14
- Terminal elimination half-lifeTime frame: At Day 14
- For Brex only, apparent cleanse and apparent volume of distributionTime frame: At Day 14
Locations
10 sites in 1 country. Site status is shown where the registry gives one.
Site not named
Little Rock, Arkansas
Site not named
Culver City, California
Site not named
Orange, California
Site not named
Washington D.C., District of Columbia
Site not named
Atlanta, Georgia
Site not named
Marlton, New Jersey
Site not named
Cincinnati, Ohio
Site not named
Cleveland, Ohio
Site not named
The Woodlands, Texas
Site not named
Orem, Utah
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.